Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab consolidation for MRD reduction in high-risk Ph-negative adult acute lymphoblastic leukemia
2016-004877-42Phase 2Active
- Sponsor
- PETHEMA
- Start
- Feb 2018
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by PETHEMA. Primary endpoint: MRD response after consolidation. Started Feb 2018; status: active.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2016-004877-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004877-42.